Advertisement

Topics

BMS’s immunotherapy drug Opdivo fails in Phase III brain cancer study

11:21 EDT 9 May 2019 | MedCity News

The drug was being tested in combination with radiation therapy among newly diagnosed patients with glioblastoma, a notoriously difficult-to-treat and invariably fatal disease.

Original Article: BMS’s immunotherapy drug Opdivo fails in Phase III brain cancer study

NEXT ARTICLE

More From BioPortfolio on "BMS’s immunotherapy drug Opdivo fails in Phase III brain cancer study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...